Abstract
It remains unclear whether there are differences in the safety and efficacy outcomes between everolimus-eluting stent (EES) and zotarolimus-eluting stent (ZES) for treatment of unprotected left main coronary artery stenosis. From the IRIS MAIN Registry (total 4253 patients), we identified 1402
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
